NCT07495657Not yet recruiting
Pre-Post Multimodal Assessment Of Severe Psoriasis Vulgaris Using Clinical, Dermoscopic And QoL Measures
Multimodal Evaluation of Severe Psoriasis Vulgaris Before and After Treatment Using Clinical, Dermoscopic, Psoriasis Disability Index, and Quality of Life Parameters
Source: ClinicalTrials.gov · Last updated 27 Mar 2026
Brief summary (registry, in English)
The goal of this observational study is to learn about the comprehensive changes in severe plaque psoriasis (Psoriasis Vulgaris) in adult participants undergoing standard treatment. The main questions it aims to answer are: How clinical signs of psoriasis, such as redness, scaling, and thickness, change after treatment? How specific skin features, visualized under dermoscopy, change after treatment? How participants' perceptions of psoriasis-related disability and overall quality of life improve after treatment? Participants will undergo standard medical treatment for severe psoriasis. Participants will be evaluated at the beginning of the study and again after treatment using clinical skin examinations, dermoscopic imaging, and validated questionnaires (Psoriasis Disability Index and quality of life parameters).
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 45 (estimated)
- First submitted
- 19 Mar 2026
- Start date
- 1 May 2026
- Primary completion date
- 1 May 2027
- Lead sponsor
- Assiut University
- Diseases
- Psoriasis
- NCT number
- NCT07495657
What you commit to
- Study type: Observational
- Planned participants: 45
- From 1 May 2026 to the primary completion date, 1 May 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- • Non cooperative patients .
- Pregnant or breastfeeding women
Who the study is looking for
- Patients ≥ 6 years of age
- Newly diagnosed patients with plaque psoriasis with affected BSA \>10%
- Indicated for a new systemic therapy (e.g., oral agent, biologics).
- Willing and able to provide informed consent for all procedures .
- At least one eligible, representative target plaque for serial dermoscopic imaging .
- Stop previous systemic therapy at least 2-3 months
Age in the registry: 6 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.